Podcasts about HCT

Andres Ambühl ist der Rekordmann des Schweizer Eishockeys. Der Bündner hält selbst internationale Bestwerte, was Anzahl Länderspiele, WM-Teilnahmen und -Partien angeht. Im Sommer 2025 gewann er in Stockholm zum dritten Mal Silber - der gegen die USA verlorene Final war für den bald 42-Jährigen das letzte Spiel der Karriere.Marc Wieser nahm nur einmal an einer WM teil: 2016. Ausser jener Saison spielte der bald 38-Jährige nie für das Nationalteam, nicht einmal in Junioren-Auswahlen. Dennoch schaffte er es zu einer grossen nationalen Karriere mit vier Meistertiteln und 1007 Spielen in der höchsten Liga.Im letzten Eisbrecher der Saison 24/25 blicken die beiden diesen Sommer zurückgetretenen Stürmer des HC Davos zurück auf ihre langen und ereignisreichen Karrieren und können auch dank ihrer seit der Kindheit bestehenden Freundschaft viele interessante und amüsante Episoden erzählen - inklusive der schwierigen Zeiten in Davos.

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.Featured Articles: Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaA new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Die ZSC Lions sind Schweizer Meister. Spiel 5 im Playoffinal endet mit einem 3:2-Erfolg der Zürcher in Lausanne. Das Best-of-7 geht damit mit 4:1 Siegen an den Titelverteidiger. Wir diskutieren mit Rapperswils Goalie Melvin Nyffeler über die Partie und vor allem die Torhüter-Optik.

CancerNetwork®, in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT)®, hosted a Twitter/X Space during the 2025 Tandem Meetings. The live conversation featured Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, and Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center. Together, they shared expert commentary on new data in CAR T-cell therapy and hematopoietic cell transplantation.With insights drawn from posters, oral abstracts, and late-breaking presentations, the session unpacked both clinical takeaways and implications for patient care.Highlights included:LBA1 – Ide-cel + lenalidomide maintenance post-transplant in MM patients“This merges two worlds,” said Banerjee. “Not a tandem in the classic sense, but a transplant followed by CAR T.”[Garfall et al., Abstract LBA-1]Abstract 50 – Real-world CAR T use in early relapsed/refractory LBCLHoltan noted, “In this cohort, no statistical survival difference was seen between second- and third-line therapy, though the curves suggest a trend.”[Rojek et al., Abstract 50]Poster 340 – CAR T targeting CD83 in breast cancerBanerjee speculated on future innovations: “If we could deliver these locally, without systemic effects, that would be a game changer.”[Betts et al., Poster 340]Poster 317 – IEC-colitis in cilta-cel-treated patientsBanerjee reflected, “We assumed steroids would help, like with GVHD. But outcomes didn't align.”[Chang Lim et al., Poster 317]Poster 572 – Driving restrictions post-CAR TBanerjee advocated for updated policy: “Patients often can't regain full independence until driving is restored—this restriction lacks strong evidence.”[Banerjee et al., Poster 572]Presentation 58 – Physical function tests to predict ICANS and mortality“These simple tools helped flag patients unlikely to benefit from CAR T,” said Holtan. “This could refine patient selection.”[Herr et al., Presentation 58]Poster 618 – HCT outcomes for MDS patients by age groupHoltan expressed optimism: “We need conditioning regimens that are effective yet gentler—especially for older patients.”[Duarte et al., Poster 618]Presentation 39 – Immune suppression trends post-HCT (18,000+ patients)Looking ahead, Holtan predicted a shift in GVHD care: “In 10 years, steroids may no longer be our go-to.”[Pidala et al., Presentation 39]Poster 516 – Patient experiences with chronic GVHD via social media listeningHoltan emphasized the human element: “We must prioritize mental health, community support, and advocacy alongside clinical treatment.”[Cowden et al., Poster 516]The discussion emphasized not only the clinical relevance of each study but also broader themes—improving quality of life, adjusting standards of care based on real-world findings, and advancing innovation through thoughtful, patient-centered research.References:Garfall AL, et al. Abstract LBA-1. Tandem 2025.Rojek AE, et al. Abstract 50. Tandem 2025.Betts BC, et al. Poster 340. Tandem 2025.Chang Lim KJ, et al. Poster 317. Tandem 2025.Banerjee R, et al. Poster 572. Tandem 2025.Herr M, et al. Presentation 58. Tandem 2025.Duarte FB, et al. Poster 618. Tandem 2025.Pidala J, et al. Presentation 39. Tandem 2025.Cowden M, et al. Poster 516. Tandem 2025.

Spiel 4 im Playoffinal endet mit einem 3:1-Heimsieg der ZSC Lions gegen Lausanne. Damit führen die Zürcher im Best-of-7 mit 3:1. Wir diskutieren mit dem früheren Goalie Lars Weibel über die Partie, aber auch über seine aktuelle Arbeit als Nationalmannschafts-Direktor.

Spiel 3 im Playoffinal zwischen dem Lausanne HC und den ZSC Lions endet mit einem 4:2-Heimsieg. Damit führen die Zürcher im Best-of-7 nur  noch 2:1. Wir diskutieren mit Michael Liniger, dem neuen Cheftrainer des EV Zug, über die Partie, aber auch über seine Arbeit beim EVZ. 

Auch Spiel 2 im Playoff-Final geht an die ZSC Lions: Sie gewinnen zuhause gegen Lausanne mit 3:2 nach Verlängerung und führen im Best-of-7 nun 2:0. Über die Partie sprechen wir mit dem früheren Profi Sven Helfenstein, der heute als Spielerberater arbeitet und bei Mysports als TV-Experte wirkt.

Spiel 1 im Playoff-Final geht an die ZSC Lions, die auswärts bei Lausanne mit 3:0 gewannen. Wir diskutieren mit Edgar Salis über die Partie sowie die Lions-Organisation.

Am siebten und letzten Tag der Playoff-Halbfinals gewinnt der Lausanne HC gegen den HC Fribourg-Gottéron Game 7 mit 5:1. Der LHC trifft damit ab Dienstag im Final auf die ZSC Lions, die sich bereits am Donnerstag gegen den HC Davos durchgesetzt hatten. Wir reden mit Stürmer Dominic Hobi über die gestrige Partie sowie über die ebenfalls bereits beendete Ligaqualifikation, in der sich der HC Ajoie gegen Swiss-League-Club Visp 4:1 durchsetzte und sich den Ligaerhalt sicherte.

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog Almost every week I hear from my male patients that their PCP doctor has scared them by telling them to stop taking testosterone pellets because their Hematocrit is too high.  Alternatively, their doctor recommended a lower dose of T. These two recommendations are those doctors who don't understand all the good that the testosterone is doing for these men. My male patients come to me for Testosterone pellets to treat their ED, lack of libido, loss of muscle, inability to think, weight gain, lack of motivation, anxiety attacks, poor stamina, arthritis, loss of balance, and basically everything that makes a man a man!  The most amazing thing is that I can treat them with ONE hormone, Testosterone in pellet form, and cure all these problems! If a man stops taking Testosterone, they get these symptoms again and have to take a multitude of drugs to feel just a fraction better! The treatment for a high H/H is simple…it is a routine removal of blood, either a blood donation or a phlebotomy (removal of 500 cc of blood) in the office, every 2-6 months to keep their H/H under control. The advice their doctors give them is going to cause them great pain and actually shorten their lives and there is little risk if any to removing blood every few months! In the event that a man demands that I lower their dose…..and I do it…the next inevitable phone call is to complain that their symptoms are coming back!  They literally blame me for the advice of their PCP! I would like to tell these men that the same doctors who could not help them with their low T are the same ones who are giving them the advice to lower or stop their testosterone therapy with T pellets.  It is human nature and especially that of doctors to try to criticize the advice of the doctor who got better results with a patient than they did! So, if you develop a condition called erythrocytosis secondary to your testosterone replacement, then you can keep your T therapy, if you are compliant and follow your testosterone doctor's directions and get your blood removed when it is scheduled.  This should prevent any severe reaction from your doctor. This is a typical response to my patient who has concerns.  However, I have given my patients many sources of written and video information about every aspect of testosterone replacement, the risks and benefits including erythrocytosis.  These include my book, Got Testosterone? was given to them on the first visit.  We also have over 650 informational blogs and videos on You Tube, FAQs and a very extensive handout given to each of them on the first visit. They just have to read! I have read your concern about erythrocytosis and testosterone replacement that was brought up by your PCP.  It is true that T replacement increases the H/H in both sexes.  It is useful if you are anemic, but if you have a genetic response to testosterone that elevates your H/H above what is considered normal, then we advise blood donation or phlebotomy every 2-6 months. It is true that the dose of T can affect the H/H, but men often need a high dose of T to feel normal. The removal of blood is low risk and effective. I am a Specialist in   Hormone Replacement Medical care with a 38-year history of replacing bioidentical hormones and 23 years of experience replacing bioidentical hormones with T and E2 pellets.  You came to me because your doctors were not helping you with the symptoms of testosterone deficiency and because I have the most experience in the Midwest. #1.    The first issue that we must always consider while we treat anyone is the primary goals for treatment, the relief of low testosterone which is why you came to me. You made an appointment with me because you had un-addressed issues that your PCP (Primary Care Doctor) didn't treat satisfactorily Your symptoms were treated with testosterone pellets successfully at a dose that is individual to you. Your health as you get older is also dependent on your blood level of free Testosterone (the total T is not significant) by delaying the diseases of aging. The level that is required to treat your symptoms is the young healthy Free T blood level of a young and healthy man. Most labs give a reference range for older men which reflects the fact that free testosterone levels drop with age. Old men don't feel well BECAUSE they have low free T.  The low free T level is why you don't feel well. Our practice has found that everyone has an ideal free T level that we try to maintain, and these are young-healthy level but not old-man level.  That is what we have been trying to achieve for our patients. #2. The second issue is a side-effect that you, as an individual, have experienced with pellets and will experience with any T replacement that you receive that is a high enough dose to treat your symptoms.  Erythrocytosis is a side effect that some men experience on any form of testosterone, however its occurrence doesn't mean you are on too much testosterone, it means you have a side effect of having a normal free T level.  Erythrocytosis is genetic, and your free T blood level stimulates the production of too many red blood cells.  We don't stop the treatment that is making you better, to treat the side effects of it.  We treat the side effects. We treat this side effect with phlebotomies to keep your H/H within the safe range.  Did your medical doctor/cardiologist tell you why this is important?  We tell you: too many red blood cells can increase the work of the heart, however the Hematologists that we consult with give us the HCT% number we should stay below is 58%.  We like to keep your HCT% below 52% but that requires you to be compliant with your regular blood donated or phlebotomized in our office (that takes an appointment). You must be compliant to keep your H/H normal. These 2 issues are at odds with one another. I cannot give a man enough testosterone to treat his symptoms, without stimulating some production of RBCs.  I have no other low T treatment that doesn't stimulate your bone marrow to make red cells BUT I do have a simple treatment to remove your extra blood cells routinely to keep you from having too many blood cells circulating. Only you can make the decision to choose health with T pellets and do phlebotomies regularly as recommended, or to stop T and allow your blood count to decrease., and your symptoms will come back. I want you to read your post-pellet instructions, locate my book Got Testosterone? and read it especially the section on Erythrocytosis, and look at FAQs (frequently asked questions) on the www.biobalanacehealth website, read related episodes of my 677 blogs and or listen to my health casts for your answers.  You can imagine how I feel when my patients don't read what I provide to them in multiple forms to answer their questions. In the future you should read the information I have given you or come in for an appointment to discuss these matters.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Anonymous: Hi Dr Cabral. I'm looking for advice to help my 8 year old daughter. She had a verucca last year that was persistent, it eventually cleared up with over the counter treatment. The verucca has come back this year and is really not shifting & it appears to be getting worse/larger. I have tried taping it, shop bought treatments and home remedies using garlic etc. What would you recommend? Thank you for sharing all of your wisdom.                                                                         Kirsten: Hi Dr. C! Thank you so much for what you do! I enjoy listening to your podcasts daily! I took the MTHfr test and I was told that I carry one abnormal copy of two Mthfr genes. It looks like I am heterozygous for both.. Can you explain to me what this means and what I need to do to treat it please? I also have Hashimotos but not sure if that's connected or not.Thank you!                                                                   Angie: Hello Dr. Cabral,My recent lab results indicate platelets low at 147 which is concerning. Gi Doctor said i have at two low labs and she is not concerned since it's a trend with prior labs. What could be wrong and what is your suggestion for a resolution ? Other labs - which are concerning Hemoglobin @16.5 (high) HCT @50 (high) Glucose @101 (high) And diagnosed with IBS.I appreciate any guidance. Thank you for all you do !                                                                                      Christina: Hi Dr. Cabral! First, thank you for your generosity with your knowledge & time & the team you have built around you. I'm so grateful for the community. Now to the question: 3 months ago I started eating chicken and beef again after 15 years of a pescatarian diet. I have noticed that since that time, my frequency of burping has increased. I thought maybe my microbiome and digestive system needed time to adjust, but also thought by 3 months it would have subsided. This is the only change I've made in my diet; all other habits are the same - sleep, frequency of workouts, environment, supplements, etc. The burps come on suddenly which can be sort of embarrassing and if I try to hold them in, it causes acid reflux. What do you suggest I do?                                                                                    Julianna: Hello! Thank you for reviewing my situation. I am female, age 22. As many women my age, I have been dealing with acne for a while, but got much worse around age 20 (didn't have much of a problem in high school). It appears to be fungal and comedonal acne all the time and some cystic acne around my period. Many small spots on my chin, forehead, and nostril area, sometimes in the area above my top lip. I've seen a dermatologist for the past 2 years, on Doxycycline pills, tretinoin cream, and clindamycin lotion. This helped clear my skin pretty well but not completely. I recently stopped all of these, I want to find more natural solutions to whatever is causing the acne, and the acne has, of course, come back. I try to eat clean and use low-tox products. What can I do to solve this?     Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3327 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.  The conversation took place during the 2025 Tandem Meeting and highlighted many significant presentations and posters on CAR T-cell therapies and transplantation, Banerjee's and Holtan's respective areas of expertise. The following trials were discussed: LBA1 - Phase II Multicenter Trial of Idecabtagene Vicleucel (Ide-cel) Followed By Lenalidomide Maintenance for Multiple Myeloma Patients with Sub-Optimal Response after an Upfront Autologous Hematopoietic Cell Transplantation: Top Line Results from the BMT CTN 1902 Clinical Trial1 “This [study] is nice because it merges 2 worlds. It's like a tandem—but not really a tandem—because you're not doing 2 transplants back-to-back. You're doing a transplant followed by CAR T-cell therapy,” said Banerjee. Abstract 50 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium2 “In a relatively small cohort, [investigators] found no difference in 9-month survival whether someone got their [CAR T cells] in second-line therapy vs third-line therapy from a statistical perspective. If you look at the curves, it looks like there is a potential benefit to second-line therapy, but there was not enough statistical power to determine a difference,” said Holtan. Poster 340 - CD83 Expression By Human Breast Cancer Mediates Effective Killing By CAR T3 “If there's a way to do [the therapy] armored and have a paracrine delivered in real time—and not given to the whole body—[so] the patient [would] have all the adverse effects and cytokine release syndrome release on their own…that would be awesome,” stated Banerjee.  Poster 317 - Risk Factors for Immune Effector Cell-Associated Enterocolitis (IEC-colitis) in Patients with Relapsed Myeloma Treated with Ciltacabtagene Autoleucel (cilta-cel)4 “From the best that we can tell, ironically, corticosteroids aren't the fix that we want them to be [for immune effector cell-associated colitis]…We were like ‘Diarrhea, whatever. Let's give some steroids and treat it like gut graft-versus-host-disease,' but these patients [didn't] respond as well [to that],” said Banerjee. Poster 572 - Post-CAR-T Driving Restrictions Appear Unnecessary after Week 4: Data from the US Multiple Myeloma Immunotherapy Consortium5 “Patients and their caregivers [who have] put their life aside for 4 weeks just to get through CAR T-cell therapy and the Risk Evaluation and Mitigation Strategies requirements are now being told ‘You're free to go, but you can't drive for 4 weeks, which means you can't get your own groceries or…go to doctor's appointments by yourself.' Basically, we argue…that this [requirement] is not evidence-based,” stated Banerjee.  Presentation 58 - Physical Function Measures Identify Non-Hodgkin Lymphoma Patients at High Risk of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and 1-Year Mortality after Chimeric Antigen Receptor T (CAR-T) Cell Therapy6 “This [presentation] highlights that even within a high [CAR-HEMATOTOX group], those patients were at extraordinarily high risk of not benefitting from CAR T-cell therapy, and these tests are so simple to do. It's going to be interesting to see if others can reproduce this,” said Holtan. Poster 618 - Comparison of Outcomes after Hematopoietic STEM Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Patients Older or Younger THAN 65 YEARS Old. a Retrospective Analysis of the Latin America Registry7 “My personal hope for this space is that our field can come up with more novel conditioning regimens such that we can ablate the marrow without causing those gastrointestinal toxicities or other organ toxicities [while] doing that so effectively that we don't even need maintenance therapies for a lot of conditions,” stated Holtan. Presentation 39 - Determinants of Immune Suppression Discontinuation in the Modern Era: A CIBMTR Analysis of 18,642 Subjects8 “I'm going to make a provocative prediction for the next paper [approximately 10 years from now]. I predict that steroids won't be the first-line therapy for acute or chronic graft-versus-host-disease,” Holtan said. Poster 516 - Patient Experiences with Chronic Graft-Versus-Host Disease and Its Treatment in the United States: A Retrospective Social Media Listening Study9 “We can still work together to make life as good as we possibly can [for patients], to improve physical function, to take away some of this mental distress, and then work together for advocacy too. [We can] help with peer support, help with resources, and help relieve some of that misunderstanding in the community,” stated Holtan. References 1.        Garfall AL, Pasquini MC, Bai L, et al. Phase II multicenter trial of idecabtagene vicleucel (ide-cel) followed by lenalidomide maintenance for multiple myeloma patients with sub-optimal response after an upfront autologous hematopoietic cell transplantation: top line results from the BMT CTN 1902 clinical trial. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract LBA-1. 2.        Rojek AE, Ahmed N, Gomez-Llobell M, et al. CAR T cell therapy in early relapsed/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract 50. 3.        Betts BC, Davilla ML, Linden AM, et al. CD83 expression by human breast cancer mediates effective killing by CAR T. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 340. 4.        Chang Lim KJ, Chhabra S, Corraes ADMS, et al. Risk factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 317. 5.        Banerjee R, Richards A, Khouri J, et al. Post-CAR-T driving restrictions appear unnecessary after week 4: data from the US multiple myeloma immunotherapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 572. 6.        Herr M, McCarthy P, Jacobsen H, et al. Physical function measures identify non-Hodgkin lymphoma patients at high risk of immune effector cell-associated neurotoxicity syndrome (ICANS) and 1-year mortality after chimeric antigen receptor T (CAR-T) cell therapy. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 58. 7.        Duarte FB, Garcia YDO, Funke VAM, et al. Comparison of outcomes after hematopoietic STEM cell transplantation (HCT) for myelodysplastic syndrome (MDS) patients older or younger THAN 65 YEARS Old. A retrospective analysis of the Latin America registry. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 618. 8.        Pidala J, DeFlilipp Z, DeVos J, et al. Determinants of immune suppression discontinuation in the modern era: a CIBMTR analysis of 18,642 subjects. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 39. 9.        Cowden M, Derrien-Connors C, Holtan S, et al. Patient experiences with chronic graft-versus-host disease and its treatment in the United States: A retrospective social media listening study. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 516.

TWiP solves the case of the man with somnolence and something extra-erythrocytic, and presents a new puzzle for you to solve. Hosts: Vincent Racaniello, Daniel Griffin, and Christina Naula Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode Join the MicrobeTV Discord server Letters read on TWiP 253 New Case 26-year-old female with no past medical history.  Patient is from Georgia in the US and is volunteering in Hérico, Guinea (town in the Lélouma Prefecture in the Labé Region of northern-central Guinea). She arrived in Guinea in December  2023.  She was taking doxycycline for malaria prophylaxis and says that she has not missed any doses On October  2024 she presented with fever and dry cough.  Lab work was done and follow up planned for the following day.  The patient slept poorly, was febrile to 104 and had ongoing cough.  The next day she went to the hospital and was evaluated in the ER for acute febrile illness of unclear etiology.   In the hospital, VS were 97.9F, BP 105/70, P 94 Oxy sat 98%, normal physical exam. She was started on Augmentin and Coartem. Pause here to think about the differential at this point and maybe some more history and what testing you might want WBC 14, Hb 13, HCT 40, PLT 285, Neut abs 8, Eos Abso0.80; BUN/creat  normal, AST normal; ALT 44, GGT 125 Stool parasite screen + for some sort of eggs, malaria smear negative, CXR with b/l infiltrates She was given a medication (vomited 30 min after dose received).  She then received a second dose of medication 5 hours after the first) and was discharged. The following day the patient returned to the ER, stating that she felt worse.  Her temperature had climbed to 104 overnight, and she developed watery diarrhea and nausea.  There were no additional episodes of vomiting.  She was given an additional dose of a medication, ibuprofen, and started on ceftriaxone 1 gm IV Q12 hrs.  During the day she continued to have low grade fevers and developed abdominal pain.  That night she was again febrile to 104 F.    She remained admitted for 5 days with ongoing symptoms of diarrhea, nighttime fevers and diffuse abdominal discomfort.  Three more malaria tests were negative (rapid test and slide review) Blood cultures collected – no growth She continued to have mild elevation of WBC and slight elevation of AST and ALT. The patient was transferred to a different hospital. They give her a different medication, and within 24 hours symptoms resolve.  What is the diagnosis and what happened here with management? Become a patron of TWiP  Send your questions and comments to twip@microbe.tv Music by Ronald Jenkees

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53.  In Part II, experts stress the importance of early consultation to optimize treatment decisions and ensure equity in access to HCT for older patients in need of a curative treatment option.    To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53. In Part I: Expanding Access to Older Patients, guests explore major advances in transplant for older patients with MDS, highlighting the recent expansion of coverage through the Centers for Medicare and Medicaid Services (CMS), a significant milestone driven by recent studies that demonstrate the safety and efficacy of HCT in patients over 65 years old. To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

This is Derek Miller, Speaking on Business. Hale Centre Theatre, born from a deep passion for theatre, is celebrated for its world-class productions. Offering musicals, plays and educational programs, it combines artistic excellence with state-of-the-art technology and craftsmanship to create unforgettable experiences. Co-founder and artistic director, Sally Dietlein, joins us with more. Sally Dietlein: At Hale Centre Theatre, we're proud of the world-class productions we've brought to Utah since 1985. We offer everything from musicals to plays in our state-of-the-art round theater, which is one of the most advanced for live performances in the world. What truly sets us apart, however, is our commitment to our community. While we started as a for-profit organization, we became a 501(c)(3) nonprofit in 1997, and that shift allowed us to grow and focus even more on giving back to Utah. Our theater isn't just a place for performances — it's a home for local talent, an economic driver and a space where everyone can feel a sense of ownership. I invite you to come see what makes Hale Centre Theatre so special. Whether you're joining us for a show or supporting the arts, you're contributing to something that enriches the entire community. Learn more at HCT.org. Derek Miller: Hale Centre Theatre continues to enrich the community with exceptional performances, blending artistic innovation and cutting-edge technology. I'm Derek Miller, with the Salt Lake Chamber, Speaking on Business. Originally aired: 12/20/24

This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.   In Part I: Strategies and Considerations, the experts discuss strategies to prioritize alternative donor sources to ensure that more patients receive HCT at optimal timepoints.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.   In Part II: Overcoming Barriers, the experts review implications for the future of donor search optimization, transplant access and health equity in an increasingly diverse patient population.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site. 

Die richtige IT-Technik schützt vor Datenverlusten und sichert damit die eigene Existenz. Aber gerade Einzelunternehmer oder kleine Firmen vernachlässigen diese und achten auf wichtige Elemente nicht. Im Gespräch mit Susanne Hasl der HCT Computertechnik aus Mindelheim zeigen wir die wichtigsten Bereiche auf, die auch "Kleinere" beachten sollten, damit nicht mal das große Erwachen kommt. Shownotes:

BUFFALO, NY- October 11, 2024 – A new #editorial was #published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.” As highlighted in this editorial, TP53 mutations (mut) occur in 10–15% of acute myeloid leukemia (AML) cases, commonly associated with therapy-related AML (t-AML) and complex cytogenetics (CG). TP53-mut AML is inherently resistant to conventional chemotherapies and continues to show a poor prognosis, even with venetoclax-based therapies. Allogeneic hematopoietic stem cell transplant (allo-HCT) remains a potential curative option, though only 10–15% of patients receive it. In a recent study, allo-HCT was the only variable significantly improving survival, despite only 16% of patients successfully bridging to it. In their editorial, researchers Talha Badar, Moazzam Shahzad, Ehab Atallah, Mark R. Litzow, and Mohamed A. Kharfan-Dabaja from the Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program at Mayo Clinic (Jacksonville, Florida) evaluated the outcomes of TP53-mutated AML patients based on data from the Consortium of Myeloid Malignancies and Neoplastic Diseases (COMMAND). The study found a “dismal” survival rate of 8.5 months, with no significant difference among treatment types, and allo-HCT was the only variable associated with improved survival. The authors also report on the “better long-term outcomes” when allo-HCT was performed during Complete Remission 1 (CR1) in previous observations. They acknowledge the limitations of their retrospective analysis, including selection bias, data heterogeneity from participating institutions, and the lack of complete molecular data prior to allo-HCT that might have influenced the results. Nevertheless, the findings are encouraging and suggest that allo-HCT improves long-term outcomes in this poor prognostic disease, where effective therapies remain limited. “In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.” DOI - https://doi.org/10.18632/oncotarget.28652 Correspondence to - Talha Badar - badar.talha@mayo.edu Video short - https://www.youtube.com/watch?v=OQue9gbqsxE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28652 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, AML, TP53 mutation, allogeneic stem cell transplant About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In this week's episode we'll discuss a novel tripartite fusion drives treatment resistance in acute promyelocytic leukemia. In some patients with atypical APL, these novel retinoic acid receptor gene fusions result in truncation of the ligand binding domain of the retinoic acid receptor protein, resulting in non-responsiveness to treatment with all-trans retinoic acid. After that: managing immune thrombotic thrombocytopenia or iTTP without therapeutic plasma exchange, or TPE. Finally, hope for motherhood after allogeneic HCT.Featured Articles: Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APLManagement of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchangeHope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

TWiP solves the case of the AIDS patient who developed fever and watery diarrhea after drinking NYC tap water, and present a new case for your sleuthing. Hosts: Vincent Racaniello and Daniel Griffin Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode Join the MicrobeTV Discord server Cryptosporidium (TWiP 18) Letters read on TWiP 239 Become a patron of TWiP  New Case Man in his 70s originally from Mainland China, then Hong Kong who has been living in the US for decades is admitted to the hospital with fever for 6 days. He reports that he saw his primary care physician in Queens and was referred to the hospital after blood work revealed a sodium level of 123 and an increased monocyte count. Pt reports drenching sweats, lots of outdoor activity walking in local parks in Queens. He reports he does not feel particularly sick. PMH-HTN, BPH PSH-neg Social-retired, no wife, has one son, no pets, no exotic exposures or recent travel VS febrile to 39.5, tachycardia, meets sepsis criteria PE -unremarkable Labs, nl wbc, eos-0, elevated neutrophils and monocytes, Na-123, elevated AST, elevated ALT, low platelets, low Hct, CT Chest A/P unremarkable Send your guesses to twip@microbe.tv with TWiP 239 in the subject line Send your questions and comments to twip@microbe.tv Music by Ronald Jenkees

In this episode of "ASTCT Talks," Dr. Shernan Holtan sits down with Dr. Samer Al-Homsi, as he shares his insights on the future of graft versus host disease (GVHD) prophylaxis, particularly in haploidentical transplantation. Dr. Al-Homsi delves into the innovative CAST regimen, which combines post-transplant cyclophosphamide, abatacept and short-duration tacrolimus. Learn about the challenges, breakthroughs and promising results that could revolutionize how we approach GVHD prevention and treatment, making a future without GVHD a reality. Listen in as we explore the potential for reducing transplant toxicities and the impact on patient care. About Dr. Samer Al-Homsi A. Samer Al-Homsi, MD, MBA, is the System Chief of Blood and Marrow Transplant and Cellular Therapy at Northwell Health Cancer Institute and serves as Director of Faculty and Academic Affairs in Medical Oncology. He is a Professor of Medicine at the Zucker School of Medicine and of Cancer Research at Feinstein Institutes of Medical Research. Previously, he was the Executive Director of Blood and Marrow Transplantation at NYU Grossman School of Medicine. Dr. Al-Homsi graduated from Damascus Medical School and trained in Hematology and Medical Oncology in France. He completed his residency at Advocate Health Care and fellowship at the University of Massachusetts. He has led programs in Malignant Hematology and Blood and Marrow Transplantation at several institutions, including NYU Langone Health. His research focuses on preventing graft-versus-host disease (GvHD), developing innovative approaches such as the CyBor and CAST regimens, particularly in haploidentical transplants. Dr. Al-Homsi aims to address healthcare disparities due to donor shortages among minority groups. Dr. Al-Homsi is also the President of the American Arab Assembly of Cellular Therapy and Transplantation (AAACTT), promoting collaboration among its members. About Dr. Shernan Holtan Dr. Holtan is a clinical/translational investigator. Her work focuses on increasing resilience, both at the tissue level to prevent and treat GVHD, and at the whole person level, designing exercise programs to mitigate cancer therapy-associated aging. In GVHD, her early work focused on epidermal growth factor and pregnancy hormones to facilitate tissue repair in GVHD, which led to a successful phase II study for the treatment of high-risk acute GVHD and discovery of the GVHD biomarker amphiregulin. More recently, she has led and published two prospective clinical trials regarding the use of PTCy as GVHD prophylaxis, the results of which are changing practice around the globe. Dr. Holtan has also been a competitive powerlifter, setting a national record in 2019. She has leveraged her knowledge regarding strength training into translational studies and clinical trials that are helping to reverse some of the damage done by high-dose chemotherapy and radiation. Through her multidimensional accomplishments, Dr. Holtan has demonstrated a unique and powerful intersection of medical research and physical resilience, redefining standards of care in HCT, and innovatively combating the deleterious effects of cancer treatment.

A 28-year-old woman presents with new onset worsening fatigue, present for approximately the last month. She is 28 weeks pregnant with her second child, has a 1.5-year-old healthy child at home, says she remembers being tired towards the end of her pregnancy with her first child, but states, “This is worse than with my last pregnancy”. She denies vaginal bleeding or discharge, abdominal pain, or other concerning issues, is sleeping about 7 hours per night, and has adequate access to nutritious food. She is not taking a prenatal vitamin, reporting, “I kept throwing up every time I took one.” During early pregnancy. PHQ-9 screening tool results are without concern.Labs results are as follows.Hemoglobin 9.2g per dl (NL=12-14)Hct=27% (NL=36-42%)Total RBC= 2.9 million (3.9 to 5.2 million cells per microliter (million/µL)MCV 75 FL (NL=80-98)MCH 22 PG (NL=27-33)RDW 18% (NL=11.5-15%)These results are most consistent with:A. Pregnancy related hemodilution.B. Folic acid deficiency anemiaC. Iron deficiency anemia.D. Beta thalassemia minor.Visit fhea.com to learn more!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance StrategiesThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance StrategiesThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance StrategiesThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance StrategiesThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance StrategiesThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance StrategiesThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance StrategiesThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Event Objectives:Review current outcome evidence on health care transition (HCT) interventions.Discuss the American Academy of Pediatrics (AAP)/American Academy of Family Physicians (AAFP)/American College of Physicians (ACP) 6 core element approach and tools for pediatric practices.Describe key lessons learned from implementing HCT performance improvement program in 2 programs.Claim CME Credit Here!

Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study. https://pubmed.ncbi.nlm.nih.gov/37607457/ ALSO AS VIDEO ON https://youtu.be/JbHS_-2sJQc CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/CarmeloGurnari

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, participants should be better able to: Summarize current guidelines and updated evidence on FLT3 mutation testing in acute myeloid leukemia (AML) and the use of next-gen FLT3 inhibitor options in newly diagnosed and relapsed/refractory AML; Implement modern treatment plans that utilize FLT3 inhibitors as standard therapy for FLT3-mutated AML patients, including in combination with intensive chemotherapy for HCT candidates or as part of novel combinatorial regimens; and Address the unique suite of adverse events associated with the use of FLT3 inhibitors in AML.

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, participants should be better able to: Summarize current guidelines and updated evidence on FLT3 mutation testing in acute myeloid leukemia (AML) and the use of next-gen FLT3 inhibitor options in newly diagnosed and relapsed/refractory AML; Implement modern treatment plans that utilize FLT3 inhibitors as standard therapy for FLT3-mutated AML patients, including in combination with intensive chemotherapy for HCT candidates or as part of novel combinatorial regimens; and Address the unique suite of adverse events associated with the use of FLT3 inhibitors in AML.

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, participants should be better able to: Summarize current guidelines and updated evidence on FLT3 mutation testing in acute myeloid leukemia (AML) and the use of next-gen FLT3 inhibitor options in newly diagnosed and relapsed/refractory AML; Implement modern treatment plans that utilize FLT3 inhibitors as standard therapy for FLT3-mutated AML patients, including in combination with intensive chemotherapy for HCT candidates or as part of novel combinatorial regimens; and Address the unique suite of adverse events associated with the use of FLT3 inhibitors in AML.

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, participants should be better able to: Summarize current guidelines and updated evidence on FLT3 mutation testing in acute myeloid leukemia (AML) and the use of next-gen FLT3 inhibitor options in newly diagnosed and relapsed/refractory AML; Implement modern treatment plans that utilize FLT3 inhibitors as standard therapy for FLT3-mutated AML patients, including in combination with intensive chemotherapy for HCT candidates or as part of novel combinatorial regimens; and Address the unique suite of adverse events associated with the use of FLT3 inhibitors in AML.

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, participants should be better able to: Summarize current guidelines and updated evidence on FLT3 mutation testing in acute myeloid leukemia (AML) and the use of next-gen FLT3 inhibitor options in newly diagnosed and relapsed/refractory AML; Implement modern treatment plans that utilize FLT3 inhibitors as standard therapy for FLT3-mutated AML patients, including in combination with intensive chemotherapy for HCT candidates or as part of novel combinatorial regimens; and Address the unique suite of adverse events associated with the use of FLT3 inhibitors in AML.

Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.

Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.

Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.

Go online to PeerView.com/RMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative intensive therapy, often consisting of potent induction/consolidation protocols followed by hematopoietic stem cell transplant (HCT), has been shown to extend survival in challenging acute myeloid leukemia (AML) settings where conventional chemotherapy options are suboptimal. In this “Clinical Consults” activity, a panel of experts provide guidance on the optimized selection of intensive upfront therapy in challenging AML subtypes and discuss how the personalized use of induction/consolidation platforms can create opportunities for subsequent HCT and lead to enhanced patient outcomes. The panelists use serial case vignettes inspired by real-world scenarios, debate the selection and use of novel cytotoxic platforms and targeted agents, and examine emerging approaches in a range of difficult-to-treat patient populations. Upon completion of this activity, participants should be better able to: Review the diagnostic, prognostic, and therapeutic implications of baseline factors such as age, genetic/molecular features, and functional status for challenging AML subtypes such as secondary AML or mutation-defined disease; Review updated clinical data surrounding novel upfront induction/consolidation regimens in diverse AML settings, including for patients with higher-risk or mutation-defined disease; Select evidence-based, personalized upfront treatment platforms for patients with challenging AML subtypes, including patients eligible for HCT; andDevelop a management plan for the unique safety considerations associated with novel upfront treatment platforms, including innovative cytotoxic and targeted regimens

Go online to PeerView.com/RMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative intensive therapy, often consisting of potent induction/consolidation protocols followed by hematopoietic stem cell transplant (HCT), has been shown to extend survival in challenging acute myeloid leukemia (AML) settings where conventional chemotherapy options are suboptimal. In this “Clinical Consults” activity, a panel of experts provide guidance on the optimized selection of intensive upfront therapy in challenging AML subtypes and discuss how the personalized use of induction/consolidation platforms can create opportunities for subsequent HCT and lead to enhanced patient outcomes. The panelists use serial case vignettes inspired by real-world scenarios, debate the selection and use of novel cytotoxic platforms and targeted agents, and examine emerging approaches in a range of difficult-to-treat patient populations. Upon completion of this activity, participants should be better able to: Review the diagnostic, prognostic, and therapeutic implications of baseline factors such as age, genetic/molecular features, and functional status for challenging AML subtypes such as secondary AML or mutation-defined disease; Review updated clinical data surrounding novel upfront induction/consolidation regimens in diverse AML settings, including for patients with higher-risk or mutation-defined disease; Select evidence-based, personalized upfront treatment platforms for patients with challenging AML subtypes, including patients eligible for HCT; andDevelop a management plan for the unique safety considerations associated with novel upfront treatment platforms, including innovative cytotoxic and targeted regimens

Go online to PeerView.com/RMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative intensive therapy, often consisting of potent induction/consolidation protocols followed by hematopoietic stem cell transplant (HCT), has been shown to extend survival in challenging acute myeloid leukemia (AML) settings where conventional chemotherapy options are suboptimal. In this “Clinical Consults” activity, a panel of experts provide guidance on the optimized selection of intensive upfront therapy in challenging AML subtypes and discuss how the personalized use of induction/consolidation platforms can create opportunities for subsequent HCT and lead to enhanced patient outcomes. The panelists use serial case vignettes inspired by real-world scenarios, debate the selection and use of novel cytotoxic platforms and targeted agents, and examine emerging approaches in a range of difficult-to-treat patient populations. Upon completion of this activity, participants should be better able to: Review the diagnostic, prognostic, and therapeutic implications of baseline factors such as age, genetic/molecular features, and functional status for challenging AML subtypes such as secondary AML or mutation-defined disease; Review updated clinical data surrounding novel upfront induction/consolidation regimens in diverse AML settings, including for patients with higher-risk or mutation-defined disease; Select evidence-based, personalized upfront treatment platforms for patients with challenging AML subtypes, including patients eligible for HCT; andDevelop a management plan for the unique safety considerations associated with novel upfront treatment platforms, including innovative cytotoxic and targeted regimens

Go online to PeerView.com/RMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative intensive therapy, often consisting of potent induction/consolidation protocols followed by hematopoietic stem cell transplant (HCT), has been shown to extend survival in challenging acute myeloid leukemia (AML) settings where conventional chemotherapy options are suboptimal. In this “Clinical Consults” activity, a panel of experts provide guidance on the optimized selection of intensive upfront therapy in challenging AML subtypes and discuss how the personalized use of induction/consolidation platforms can create opportunities for subsequent HCT and lead to enhanced patient outcomes. The panelists use serial case vignettes inspired by real-world scenarios, debate the selection and use of novel cytotoxic platforms and targeted agents, and examine emerging approaches in a range of difficult-to-treat patient populations. Upon completion of this activity, participants should be better able to: Review the diagnostic, prognostic, and therapeutic implications of baseline factors such as age, genetic/molecular features, and functional status for challenging AML subtypes such as secondary AML or mutation-defined disease; Review updated clinical data surrounding novel upfront induction/consolidation regimens in diverse AML settings, including for patients with higher-risk or mutation-defined disease; Select evidence-based, personalized upfront treatment platforms for patients with challenging AML subtypes, including patients eligible for HCT; andDevelop a management plan for the unique safety considerations associated with novel upfront treatment platforms, including innovative cytotoxic and targeted regimens

Overview Hematocrit Normal Value Range Pathophysiology Special considerations Elevations in lab results Decreased HCT levels Nursing Points General Normal value range HCT measured in percentage Males – 41-50% Females – 36-44% Pathophysiology Measurement of total pRBCs compared to rest of blood volume Helps to indicate anemia Often measured with HGB (hemoglobin) Special considerations Lavender top tube (EDTA) Be cautious with technique Do not force sample into tube Can cause hemolysis Alters results Causes of HCT elevation Dehydration Change in % compared to total blood volume Respiratory disease COPD Pulmonary fibrosis Increased need for oxygen -> increased need for RBC production Polycythemia vera RBC overproduction due to bone marrow cancer Treatment includes bloodletting and increasing water consumption (also some medications) Causes of decreased HCT Blood loss Trauma Hemorrhage Treatment Stop bleeding Transfuse blood Anemia Kidney disease Decrease in EPO production Treatment Supplement with EPO Pregnancy Relative to increase total blood volume Leukemia Decreased bone marrow production causes ↓ RBC Treat leukemia via oncology pathways Chemotherapy Radiation Bone marrow transplant Assessment Assess for signs of anemia Tachycardia Fatigue Shortness of breath Decreased SaO2 Pallor Therapeutic Management Blood transfusions as necessary Treat primary cause of anemia Use oncologic methods to treat leukemia Bloodletting (phlebotomy) for polycythemia patients Nursing Concepts Lab Values Oxygenation

A new review paper was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Systemic AL amyloidosis: current approach and future direction.” In this review, researchers Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain from SUNY Upstate Medical University, University of Texas MD Anderson Cancer Center, Monmouth Medical Center, University of Balamand, Cleveland Clinic Ohio, UnityPoint Methodist, Houston Methodist Cancer Center, and Cleveland Clinic Florida report the literature on the latest treatment updates of Systemic Light chain (AL) amyloidosis and the ongoing clinical trials highlighting the future treatments. “In this manuscript, we discuss the general approach towards treating patients with amyloidosis and dive into the future perspectives in this multi-systemic disease.” Systemic AL amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. It is a fatal disease and if not diagnosed and treated early can lead to organ failure and potentially death. The renal system along with the cardiovascular system are the most common organs involved, but other organs such as the gut and liver can be involved as well. The initial evaluation of patients requires confirming the diagnosis with tissue biopsy and staining with Congo red followed by confirmatory typing with mass spectrometry of the Congo red positive tissue. Then establishing the extent of the organs involvement by various staging and biomarkers testing. The treatment options and the tolerability of therapy depend on the disease staging, frailty and co-morbidities. The autologous hematopoietic cell transplantation (HCT) after high dose melphalan therapy is an effective strategy which is usually done after initial bortezomib induction therapy. Unfortunately, most systemic AL amyloidosis patients are not candidates for HCT due to frailty, old age, multi-organ involvement, and renal or heart failure at the time of diagnosis. While it is widely accepted that the patients need to be treated until they achieve complete hematologic response, the maintenance therapy after HCT is not well established in AL amyloidosis. “The relationship between AL amyloidosis and MGUS is less clear, but some studies suggest that the risk of developing AL amyloidosis may be increased in patients with MGUS. It is important for patients with these conditions to undergo regular monitoring and evaluation for signs of AL amyloidosis, as early diagnosis and treatment can improve outcomes.” DOI - https://doi.org/10.18632/oncotarget.28415 Correspondence to - Chakra P. Chaulagain - chaulac@ccf.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28415 Keywords - amyloidosis, management About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

The average survival rate for patients with myelofibrosis is six years. But this varies based on potential treatments. There are no drugs that can modify the outcome for myelofibrosis, and the only treatment that leads to cure is an allogeneic hematopoietic cell transplantation (allo-HCT). However, because of the high rates of morbidity and mortality, this treatment must be carefully considered based on the patient. CANCER BUZZ spoke to Gabriela S. Hobbs. MD, Assistant Professor of Medicine, Harvard Medical School, and Clinical Director of Leukemia, Massachusetts General Hospital in Boston, MA. Listen as Dr. Hobbs discusses symptom scoring, risk stratification, and effective practices in building a strong myelofibrosis program. “…If a patient is higher risk, they should be referred to transplant; also patients who are high risk are more likely to have low blood counts, low platelets, and low red blood cells that may also influence how these patients are treated.” – Gabriela S. Hobbs. MD  This project is supported by AbbVie and GSK.   Gabriela S. Hobbs. MD Assistant Professor of Medicine Harvard Medical School Clinical Director of Leukemia Massachusetts General Hospital Boston, MA Resources:  Leukemia & Lymphoma Society MPN Research Foundation  

In this episode, Dr. Aaron Carroll talks with Hugh Lee, associate professor of biomedical engineering and director of the Center for Implantable Devices at Purdue University. They discuss how research translates into new implantable medical devices, including a device Lee is working on that can sense when the wearer is experiencing an opioid overdose and deliver a dose of life-saving Naloxone, as well as how engineers can collaborate with clinicians to drive further innovation in the field. Transcript: bit.ly/3H3Qkjl This Healthcare Triage podcast episode is co-sponsored by Indiana University School of Medicine, whose mission is to advance health in the state of Indiana and beyond by promoting innovation and excellence in education, research, and patient care, and the Indiana Clinical and Translational Sciences Institute, a three way partnership among Indiana University, Purdue University and the University of Notre Dame, striving to make Indiana a healthier state by empowering research through pilot funding, research education and training. More information on the Indiana CTSI can be found by visiting IndianaCTSI.org.

Episode Sponsor:---This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: CLICK HERE---Episode Overview: As someone who has seen firsthand the struggles patients face in navigating care, and the burnout clinicians and staff experience due to unstandardized 1:1 conversations, our next guest knew something had to change. Meghan Nechrebecki, CEO of Health Care Transformation, joins us to discuss her passion for finding solutions to systemic healthcare challenges, and how her team at HCT is revolutionizing the way care is delivered through innovative digital video technology. Join us to learn how Meghan and the HCT team are not only making healthcare more effective and efficient for patients but also reducing burnout and improving the overall experience for clinicians and staff by implementing asynchronous video technology. Let's go! Episode Highlights:How did HCT startThe responses Meghan first received about HCTThe gaps in ensuring a value-based careWho is HCT, and the benefits it brings to clinicians and patientsThe financial ROI of async video technologyMeghan's vision for the industry and where HCT is headingAbout our Guest: Meghan Nechrebecki, MSPH, is the founder and CEO of Health Care Transformation. She is a leading healthcare administration expert who has been solving complex systemic healthcare challenges at top institutions for over a decade, including UCLA Health, Privia Health, The Advisory Board Company, and CareFirst BlueCross BlueShield. Her expertise lies in healthcare systems improvement, healthcare analytics, value-based care, population health, and digital marketing. She earned her MSPH from Johns Hopkins Bloomberg School of Public Health where she was a Delta Omega Alpha scholar and she earned her B.S. from the University of Wisconsin-Madison in Biochemistry and Spanish where she was a Hilldale Scholar. Check out Meghan's Ted Talk “Shaping the Future of Health Care”. She has been a top speaker at conferences including ViVE, HIMSS, and the Healthcare Facilities Symposium. She has been featured on many shows, podcasts, and written publications including Good Morning LaLa Land, Business Rockstars, Thrive Global, Authority Magazine, Medical Economics, and more. Health Care Transformation is her first company.Links Supporting This Episode:Health Care Transformation website: CLICK HEREMeghan Nechrebecki, MSPH LinkedIn page: CLICK HEREMeghan Nechrebecki, MSPH Twitter page: CLICK HERELink mentioned during the interview: https://hctdigitalcare.com/nurse-repetition/Mike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: